Interstitial Lung Disease Associated with Docetaxel in a Patient Treated for Breast Cancer—A Case Report

Pankowska-Supryn, Monika; Załęska, Monika; Roszkowska-Sliz, Barbara; Roszkowski‐Śliż, Kazimierz

doi:10.5603/piap.2015.0060

Cited by 8 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the chemotherapeutics most associated with inducing RP, especially taxanes have been identified, either alone [29] or as part of combined schedules with other agents, as reported by several studies and case reports in the past [18][19][20][29][30][31]. However, our recent and previous findings [11] regarding the absence of clinically relevant RP induced by taxanes are supported by other studies like that of Yu et al [20], who investigated a cohort of 524 breast cancer patients receiving FAC (5-FU, doxorubicin, cyclophosphamide) with or without paclitaxel and subsequent RT.…”

Section: Discussionmentioning

confidence: 99%

Systematic risk analysis of radiation pneumonitis in breast cancer: role of cotreatment with chemo-, endocrine, and targeted therapy

et al. 2022

View full text Add to dashboard Cite

Purpose A major complication of sequential and concomitant chemoradiation in breast cancer treatment is interstitial pneumonitis induced by radiation therapy (RT), systemic therapy, or a combination of both. Dose and volume of co-irradiated lung tissue directly correlate with the risk of radiation pneumonitis. Especially in case of combined treatment, it is often unclear which of the used therapeutic agents promote pneumonitis. Methods This was a prospective monocentric study including 396 breast cancer patients. A systematic analysis of single and combined therapeutic measures was performed in order to identify treatment-related factors enhancing the risk of pneumonitis post RT. Results Overall incidence of pneumonitis of any grade was 38%; 28% were asymptomatic (grade 1) and 10% were symptomatic (> grade 1). Pneumonitis > grade 2 did not occur. Beside age, smoking status, and mean lung dose, the combined treatment with goserelin and tamoxifen significantly enhanced the risk of pneumonitis in a supra-additive pattern (odds ratio [OR] 4.38), whereas each agent alone or combined with other drugs only nonsignificantly contributed to a higher pneumonitis incidence post RT (OR 1.52 and OR 1.16, respectively). None of the other systemic treatments, including taxanes, increased radiation pneumonitis risk in sequential chemoradiation. Conclusion Common treatment schedules in sequential chemoradiation following breast-conserving surgery only moderately increase lung toxicity, mainly as an asymptomatic complication, or to a minor extent, as transient pneumonitis ≤ grade 2. However, combined treatment with tamoxifen and the LHRH analog goserelin significantly increased the risk of pneumonitis in breast cancer patients after chemoradiation. Thus, closer surveillance of involved patients is advisable.

show abstract

Section: Discussionmentioning

confidence: 99%

Systematic risk analysis of radiation pneumonitis in breast cancer: role of cotreatment with chemo-, endocrine, and targeted therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Although the exact mechanism of lung injury is debatable, the most common pattern of lung injury described is that of hypersensitivity pneumonitis. [9] Some studies have reported that bronchoscopy and bronchoalveolar lavage may give some evidence to support the diagnosis of drug-induced pneumonitis based on lymphocytic alveolitis, leukocytosis, and a low CD4/CD8 ratio. [4] Transbronchial lung biopsy may show nonspecific alveolar and interstitial edema with mononuclear cellular infiltrate.…”

Section: Discussionmentioning

confidence: 99%

Docetaxel-Induced Lung Injury: An Under-Recognized Complication of a Commonly Used Chemotherapeutic Agent

Manuprasad

Ganesan

Mahajan

et al. 2019

Indian Journal of Medical and Paediatric Oncology

View full text Add to dashboard Cite

Background: Docetaxel-induced pneumonitis is a rare, but potentially serious complication of a commonly used chemotherapeutic agent. Methods: We performed an audit of patients with suspected docetaxel pneumonitis from the tertiary cancer center. Results: Out of 477 patients who received docetaxel over a 1 year period, eight patients (1.7%) developed lung injury. All patients (median age: 43 years [34–65]) had breast cancer (four metastatic on palliative docetaxel, two were on neoadjuvant, and two were on adjuvant therapy) and had received a median of three cycles of docetaxel 75 mg/m2 in a 3 weekly schedule (7 as single agent and 1 in combination with cyclophosphamide). One patient had the preexisting pulmonary disease (localized bronchiectasis), and four had received prior radiation to the chest wall or dorsal spine. The median time from administration of the last dose was 16 days (8–28). Most ( n = 6/8, 75%) required hospitalization. Three patients with CTCAE Grade 3 pneumonitis required oxygen support. Radiology showed a pattern of interstitial pneumonitis in most patients. All the patients responded to steroids and follow-up imaging showed resolution of infiltrates. The median duration of hospital stay was 8.5 days (7–18 days). There was no mortality due to this condition. Conclusions: Drug-induced lung injury should be considered in patients presenting with respiratory symptoms after administration of docetaxel. Timely initiation of steroids could reduce complications.

show abstract

“…In the same way, docetaxel is classified as a tetracyclic diterpenoid and taxoid antineoplastic agent, which is utilized in the medical field for the management of various forms of cancer. These include locally advanced or metastatic breast cancer, metastatic prostate cancer, gastric adenocarcinoma, and head and neck cancer (Pankowska-Supryn et al, 2015). The pharmaceutical compound known as alitretinoin, which is derived from vitamin A, is utilized in the treatment of Kaposi's sarcoma (Bodsworth et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

Monoterpenoids: An upcoming class of therapeutic agents for modulating cancer metastasis

Mathur,

Meena,

Luqman

2023

Phytotherapy Research

View full text Add to dashboard Cite

Monoterpenoids, a sub‐class of terpenoids, are secondary metabolites frequently extracted from the essential oils of aromatic plants. Their antitumor properties including antiproliferative, apoptotic, antiangiogenic, and antimetastatic effects along with other biological activities have been the subject of extensive study due to their diverse characteristics. In recent years, numerous investigations have been conducted to understand its potential anticancer impacts, specifically focusing on antiproliferative and apoptotic mechanisms. Metastasis, a malignancy hallmark, can exert either protective or destructive influences on tumor cells. Despite this, the potential antimetastatic and antiangiogenic attributes of monoterpenoids need further exploration. This review focuses on specific monoterpenoids, examining their effects on metastasis and relevant signaling pathways. The monoterpenoids exhibit a high level of complexity as natural products that regulate metastatic proteins through various signaling pathways, including phosphoinositide 3‐kinase/protein kinase B/mammalian target of rapamycin, mitogen‐activated protein kinase/extracellular signal‐regulated kinase/jun N‐terminal kinase, nuclear factor kappa B, vascular endothelial growth factor, and epithelial mesenchymal transition process. Additionally, this review delves into the biosynthesis and classification of monoterpenoids, their potential antitumor impacts on cell lines, the plant sources of monoterpenoids, and the current status of limited clinical trials investigating their efficacy against cancer. Moreover, monoterpenoids depict promising potential in preventing cancer metastasis, however, inadequate clinical trials limit their drug usage. State‐of‐the‐art techniques and technologies are being employed to overcome the challenges of utilizing monoterpenoids as an anticancer agent.

show abstract

Interstitial Lung Disease Associated with Docetaxel in a Patient Treated for Breast Cancer—A Case Report

Cited by 8 publications

References 13 publications

Systematic risk analysis of radiation pneumonitis in breast cancer: role of cotreatment with chemo-, endocrine, and targeted therapy

Systematic risk analysis of radiation pneumonitis in breast cancer: role of cotreatment with chemo-, endocrine, and targeted therapy

Docetaxel-Induced Lung Injury: An Under-Recognized Complication of a Commonly Used Chemotherapeutic Agent

Monoterpenoids: An upcoming class of therapeutic agents for modulating cancer metastasis

Contact Info

Product

Resources

About